Juno boosts cellular therapy partnerships | Chemical & Engineering News
Volume 94 Issue 16 | p. 15 | Concentrates
Issue Date: April 18, 2016

Juno boosts cellular therapy partnerships

Department: Business
Keywords: oncology, pharmaceuticals, biotech, cancer immunotherapy, CARTs

Juno Therapeutics will collect $50 million now that Celgene has exercised an option to develop its cellular therapies targeting CD19 outside of North America and China. Juno’s CD19 portfolio includes three drug candidates; one, JCAR015, is in Phase II studies to treat acute lymphoblastic leukemia. Last year, Celgene paid $1 billion for the rights to opt in to Juno’s cellular therapies. Separately, Juno and WuXi AppTec have started JW Biotechnology in China to pair Juno’s cellular therapy technology with WuXi’s R&D and manufacturing expertise.

 
Chemical & Engineering News
ISSN 0009-2347
Copyright © American Chemical Society

Leave A Comment

*Required to comment